The nurse is caring for a client with a history of rheumatoid arthritis who reports morning stiffness. Which intervention should the nurse include?

Choice A reason: Difficulty with urination is not a primary concern for pyridostigmine, a cholinesterase inhibitor used in myasthenia gravis to enhance neuromuscular transmission. While cholinergic side effects may include urinary urgency, this is not a pre-administration priority compared to oral intake, which affects absorption and efficacy.

Choice B reason: Recent oral intake is critical before administering pyridostigmine, as food can delay its absorption, reducing effectiveness in myasthenia gravis. Taking it 30–60 minutes before or 2 hours after meals ensures optimal plasma levels, improving muscle strength, making this the priority information to obtain.

Choice C reason: Trouble sleeping is not directly relevant to pyridostigmine administration. While cholinergic side effects like diarrhea may disrupt sleep, this is a secondary concern. Ensuring proper timing with oral intake is critical for therapeutic efficacy, as absorption impacts symptom control in myasthenia gravis.

Choice D reason: Unexplained weight loss may indicate myasthenia gravis progression or other issues but is not a pre-administration concern for pyridostigmine. Timing with oral intake directly affects the drug’s pharmacokinetics, ensuring effective muscle strength improvement, making weight loss less urgent to assess before dosing.

Choice A reason: Neutropenia, a low neutrophil count, is a common chemotherapy side effect due to bone marrow suppression, increasing infection risk. Monitoring neutrophil counts is critical, as infections in breast cancer patients can be life-threatening, making it the priority side effect to assess.

Choice B reason: Hypertension is not a typical chemotherapy side effect, though some agents cause cardiovascular effects. Neutropenia is more common, compromising immunity, making it the priority to monitor, as infections pose an immediate threat in breast cancer patients on chemotherapy.

Choice C reason: Hyperkalemia is rare with chemotherapy, except in tumor lysis syndrome. Neutropenia is a frequent side effect, increasing infection risk due to marrow suppression, making it the priority to monitor, as it directly impacts patient safety during breast cancer treatment.

Choice D reason: Weight gain is not a primary chemotherapy side effect; weight loss is more common due to nausea. Neutropenia is critical to monitor, as low neutrophils increase infection risk, requiring urgent intervention in breast cancer patients undergoing chemotherapy.